David Dai
Stock Analyst at UBS
(4.30)
# 1,327
Out of 4,486 analysts
101
Total ratings
62.5%
Success rate
16.4%
Average return
Main Sectors:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASX: TLX Telix Pharmaceuticals Limited | Maintained: Buy | $31.00 | $16.65 | +86.19% | 14 | Jul 1, 2026 | |
| CLDX Celldex Therapeutics | Maintained: Buy | $45 | $39.93 | +12.70% | 2 | Jun 16, 2026 | |
| NUVL Nuvalent | Downgraded: Hold | $138 → $124 | $123.77 | +0.19% | 6 | Jun 10, 2026 | |
| CGEM Cullinan Therapeutics | Initiated Coverage: Buy | $24 | $18.15 | +32.23% | 7 | Jun 8, 2026 | |
| NBTX Nanobiotix | Maintained: Hold | $30 | $38.77 | -22.62% | 5 | Jun 4, 2026 | |
| KURA Kura Oncology | Maintained: Buy | $15 | $11.99 | +25.10% | 7 | Jun 3, 2026 | |
| BNTX BioNTech SE | Upgraded: Buy | $135 | $94.29 | +43.18% | 1 | May 27, 2026 | |
| ENGN enGene Therapeutics | Maintained: Hold | $9 → $2 | $1.92 | +4.17% | 4 | May 14, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintained: Buy | $38 → $37 | $23.24 | +59.21% | 4 | May 13, 2026 | |
| CGON CG Oncology | Maintained: Buy | $90 | $69.20 | +30.06% | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $69 → $15 | $16.18 | -7.26% | 2 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.5 | $0.4817 | +211.40% | 2 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $7 → $8 | $3.42 | +133.92% | 3 | Mar 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $2 → $4 | $4.35 | -8.05% | 3 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $90 → $128 | $119.24 | +7.35% | 2 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $34 | $79.77 | -57.38% | 3 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 → $33 | $15.88 | +107.81% | 7 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $26 → $23 | $24.40 | -5.74% | 5 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $546 | $522.25 | +4.55% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $112 | $136.36 | -17.86% | 1 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 | $40.51 | +23.43% | 3 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | ¥2,690 | $9,687.00 | n/a | 6 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | ¥34,600 | $67,280.00 | n/a | 1 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | ¥3,900 | $3,494.00 | n/a | 1 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $3.50 | n/a | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $40 → $5 | $4.75 | n/a | 2 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $3.38 | n/a | 1 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $54 | $15.67 | n/a | 2 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $28 | $8.62 | n/a | 1 | Mar 30, 2022 |
Telix Pharmaceuticals Limited
Jul 1, 2026
Maintained: Buy
Price Target: $31.00
Current: $16.65
Upside: +86.19%
Celldex Therapeutics
Jun 16, 2026
Maintained: Buy
Price Target: $45
Current: $39.93
Upside: +12.70%
Nuvalent
Jun 10, 2026
Downgraded: Hold
Price Target: $138 → $124
Current: $123.77
Upside: +0.19%
Cullinan Therapeutics
Jun 8, 2026
Initiated Coverage: Buy
Price Target: $24
Current: $18.15
Upside: +32.23%
Nanobiotix
Jun 4, 2026
Maintained: Hold
Price Target: $30
Current: $38.77
Upside: -22.62%
Kura Oncology
Jun 3, 2026
Maintained: Buy
Price Target: $15
Current: $11.99
Upside: +25.10%
BioNTech SE
May 27, 2026
Upgraded: Buy
Price Target: $135
Current: $94.29
Upside: +43.18%
enGene Therapeutics
May 14, 2026
Maintained: Hold
Price Target: $9 → $2
Current: $1.92
Upside: +4.17%
Syndax Pharmaceuticals
May 13, 2026
Maintained: Buy
Price Target: $38 → $37
Current: $23.24
Upside: +59.21%
CG Oncology
May 8, 2026
Maintained: Buy
Price Target: $90
Current: $69.20
Upside: +30.06%
Apr 15, 2026
Downgraded: Hold
Price Target: $69 → $15
Current: $16.18
Upside: -7.26%
Apr 2, 2026
Maintained: Hold
Price Target: $1.5
Current: $0.4817
Upside: +211.40%
Mar 18, 2026
Rated: Buy
Price Target: $7 → $8
Current: $3.42
Upside: +133.92%
Mar 5, 2026
Rated: Hold
Price Target: $2 → $4
Current: $4.35
Upside: -8.05%
Mar 3, 2026
Maintained: Buy
Price Target: $90 → $128
Current: $119.24
Upside: +7.35%
Jan 7, 2026
Downgraded: Hold
Price Target: $40 → $34
Current: $79.77
Upside: -57.38%
Nov 10, 2025
Maintained: Buy
Price Target: $30 → $33
Current: $15.88
Upside: +107.81%
Nov 10, 2025
Maintained: Buy
Price Target: $26 → $23
Current: $24.40
Upside: -5.74%
Nov 7, 2025
Maintained: Buy
Price Target: $546
Current: $522.25
Upside: +4.55%
Oct 31, 2025
Reiterated: Hold
Price Target: $112
Current: $136.36
Upside: -17.86%
Oct 24, 2025
Maintained: Buy
Price Target: $50
Current: $40.51
Upside: +23.43%
Apr 2, 2025
Maintained: Hold
Price Target: ¥2,690
Current: $9,687.00
Upside: n/a
Feb 26, 2025
Reiterated: Buy
Price Target: ¥34,600
Current: $67,280.00
Upside: n/a
Jan 15, 2025
Initiated Coverage: Buy
Price Target: ¥3,900
Current: $3,494.00
Upside: n/a
Sep 29, 2022
Initiated Coverage: Buy
Price Target: $5
Current: $3.50
Upside: n/a
Jul 18, 2022
Downgraded: Hold
Price Target: $40 → $5
Current: $4.75
Upside: n/a
May 16, 2022
Maintained: Buy
Price Target: $40
Current: $3.38
Upside: n/a
May 9, 2022
Maintained: Buy
Price Target: $54
Current: $15.67
Upside: n/a
Mar 30, 2022
Initiated Coverage: Buy
Price Target: $28
Current: $8.62
Upside: n/a